Moss Genomics Announces Listing on the OTC Markets
Moss Genomics (CSE: MOSS) (OTCQB: MSSGF) (FSE: F73) has announced its listing on the OTC Markets under the ticker MSSGF. This strategic move aims to enhance share liquidity and increase accessibility for U.S.-based investors by enabling trading through U.S. broker-dealers.
The company, focused on biotechnology, is developing next-generation genomics products for personal health data management. Their current project includes testing a beta version of Perennial, a consumer platform that provides personalized health insights from blood test results based on key biomarkers.
Moss Genomics will maintain its listings on the Canadian Securities Exchange (CSE: MOSS) and Frankfurt Stock Exchange (FSE: F73).
Moss Genomics (CSE: MOSS) (OTCQB: MSSGF) (FSE: F73) ha annunciato la sua quotazione sui mercati OTC con il ticker MSSGF. Questa mossa strategica mira a migliorare la liquidità delle azioni e aumentare l'accessibilità per gli investitori statunitensi, consentendo il trading tramite broker-dealer americani.
L'azienda, focalizzata sulla biotecnologia, sta sviluppando prodotti genomici di nuova generazione per la gestione dei dati sulla salute personale. Il loro progetto attuale include il test di una versione beta di Perennial, una piattaforma per i consumatori che fornisce approfondimenti sulla salute personalizzati basati sui risultati dei test del sangue e su biomarcatori chiave.
Moss Genomics manterrà le sue quotazioni sulla Canadian Securities Exchange (CSE: MOSS) e sulla Borsa di Francoforte (FSE: F73).
Moss Genomics (CSE: MOSS) (OTCQB: MSSGF) (FSE: F73) ha anunciado su cotización en los mercados OTC bajo el ticker MSSGF. Este movimiento estratégico tiene como objetivo mejorar la liquidez de las acciones y aumentar la accesibilidad para los inversores basados en EE. UU. al permitir el comercio a través de corredores de bolsa estadounidenses.
La empresa, centrada en la biotecnología, está desarrollando productos genómicos de nueva generación para la gestión de datos de salud personal. Su proyecto actual incluye la prueba de una versión beta de Perennial, una plataforma para consumidores que proporciona información sobre la salud personalizada a partir de los resultados de pruebas de sangre basadas en biomarcadores clave.
Moss Genomics mantendrá sus cotizaciones en la Canadian Securities Exchange (CSE: MOSS) y en la Bolsa de Frankfurt (FSE: F73).
Moss Genomics (CSE: MOSS) (OTCQB: MSSGF) (FSE: F73)는 MSSGF라는 티커로 OTC 마켓에 상장되었다고 발표했습니다. 이 전략적 결정은 주식 유동성을 높이고 미국 투자자들이 미국 중개인을 통해 거래할 수 있도록 하여 접근성을 증가시키는 것을 목표로 합니다.
생명공학에 중점을 둔 이 회사는 개인 건강 데이터 관리를 위한 차세대 유전체학 제품을 개발하고 있습니다. 현재 프로젝트는 주요 바이오마커를 기반으로 한 혈액 검사 결과에서 개인화된 건강 통찰력을 제공하는 소비자 플랫폼 Perennial의 베타 버전을 테스트하는 것을 포함합니다.
Moss Genomics는 Canadian Securities Exchange (CSE: MOSS)와 Frankfurt Stock Exchange (FSE: F73)에서의 상장을 유지할 것입니다.
Moss Genomics (CSE: MOSS) (OTCQB: MSSGF) (FSE: F73) a annoncé son inscription sur les marchés OTC sous le ticker MSSGF. Ce mouvement stratégique vise à améliorer la liquidité des actions et à accroître l'accessibilité pour les investisseurs basés aux États-Unis en permettant le trading via des courtiers américains.
L'entreprise, axée sur la biotechnologie, développe des produits de génomique de nouvelle génération pour la gestion des données de santé personnelle. Leur projet actuel inclut le test d'une version bêta de Perennial, une plateforme pour consommateurs qui fournit des informations de santé personnalisées à partir des résultats de tests sanguins basés sur des biomarqueurs clés.
Moss Genomics maintiendra ses inscriptions à la Canadian Securities Exchange (CSE: MOSS) et à la Bourse de Francfort (FSE: F73).
Moss Genomics (CSE: MOSS) (OTCQB: MSSGF) (FSE: F73) hat seine Listung an den OTC-Märkten unter dem Ticker MSSGF bekannt gegeben. Dieser strategische Schritt zielt darauf ab, die Liquidität der Aktien zu erhöhen und die Zugänglichkeit für in den USA ansässige Anleger zu verbessern, indem der Handel über US-Broker-Dealer ermöglicht wird.
Das Unternehmen, das sich auf Biotechnologie konzentriert, entwickelt Produkte der nächsten Generation im Bereich Genomik für das Management persönlicher Gesundheitsdaten. Ihr aktuelles Projekt umfasst die Testung einer Beta-Version von Perennial, einer Verbraucherplattform, die personalisierte Gesundheitsinformationen aus Bluttestergebnissen basierend auf wichtigen Biomarkern bereitstellt.
Moss Genomics wird seine Listungen an der Canadian Securities Exchange (CSE: MOSS) und der Frankfurter Wertpapierbörse (FSE: F73) beibehalten.
- Expanded market access through OTC Markets listing
- Potential for increased share liquidity through U.S. broker-dealer trading
- Enhanced visibility to international investors
- Perennial platform still in beta testing phase
- No revenue or commercial products mentioned
Vancouver, British Columbia--(Newsfile Corp. - April 11, 2025) - Moss Genomics Inc. (CSE: MOSS) (OTCQB: MSSGF) (FSE: F73) (the "Company" or "Moss") is pleased to announce that its common shares are now listed for trading on the OTC Markets under the ticker MSSGF. This milestone significantly expands Moss's accessibility for U.S.-based investors and enhances overall share liquidity by enabling trading through U.S. broker-dealers.
The listing on the OTC Markets is part of Moss's broader strategy to align with global capital markets while increasing visibility and participation from the international investment community.
Moss Genomics is a biotechnology company developing next-generation genomics products that empower individuals to gain greater control over their personal health data. The Company is currently testing a beta version of Perennial, a consumer-focused platform that allows users to upload their blood test results and receive personalized health insights based on key biomarkers.
The Company's shares will continue to trade on the Canadian Securities Exchange (CSE) under the symbol MOSS and the Frankfurt Stock Exchange (FSE) under the symbol F73.
For more information on Moss Genomics, please visit: https://mossgenomics.com
To view the OTC Markets profile: https://www.otcmarkets.com/stock/MSSGF/overview
About Moss Genomics Inc.
Moss Genomics is a biotechnology company focused on genomics and microbiome research to develop advanced genetic insights and solutions. The company leverages blockchain technology to enhance security and user control over genomic information. Along with its genomics-focused products, Moss Genomics deploys an Ethereum accumulation strategy as part of its treasury management, currently holding 160 ETH on its balance sheet.
For further information concerning Moss and its business, please view the Company's website at https://mossgenomics.com/ and its SEDAR+ profile at www.sedarplus.ca or contact us at:
CONTACT INFORMATION
Moss Genomics Inc.
Jack Liu, Chief Executive Officer and Director
Email: invest@mossgenomics.com
Telephone: 604-710-0124
The CSE has neither approved nor disapproved the contents of this news release. Neither the CSE nor its Market Regulator (as that term is defined in the policies of the CSE) accepts responsibility for the adequacy or accuracy of this release.
Forward-Looking Information
This release includes certain statements and information that may constitute forward-looking information within the meaning of applicable Canadian securities laws. Forward-looking statements relate to future events or future performance and reflect the expectations or beliefs of management of the Company regarding future events. Generally, forward-looking statements and information can be identified by the use of forward-looking terminology such as "intends" or "anticipates", or variations of such words and phrases or statements that certain actions, events or results "may", "could", "should", "would" or "occur". This information and these statements, referred to herein as "forward‐looking statements", are not historical facts, are made as of the date of this news release and include without limitation, statements regarding discussions of future plans, estimates and forecasts and statements as to management's expectations and intentions with respect to, among other things: the Company's intention to leverage the blockchain to advance its genomics business; the Company's belief that blockchain technology will enhance data security, privacy, and user control over genomic information; the Company's belief that its product offerings will make genetic insights more accessible and secure; the Company's belief that Ethereum will represent a viable alternative to traditional fiat currencies as part of the Company's treasury management system; and that the Company's listing on the OTC Markets will increase visibility and participation from the international investment community.
These forward‐looking statements involve numerous risks and uncertainties and actual results might differ materially from results suggested in any forward-looking statements. These risks and uncertainties include, among other things: the risk that the Company will be unable to utilize the blockchain in an effective manner for the advancement of its genomics business; the risk that the blockchain technology will not notably enhance data security, privacy or user control over genetic information; the risk that the Company's product offerings are unable to make genetic insights more accessible or secure; the risk that Ethereum will not represent a viable alternative to traditional fiat currencies for use in a treasury management system; and the risk that the OTC Markets listing will not create a notable increase in visibility and participation from the international investment community.
In making the forward looking statements in this news release, the Company has applied several material assumptions, including without limitation, that: blockchain technologies can be effectively implemented into the Company's genomics business model and can be implemented in a cost-effective and timely manner; the privacy and security offered by decentralized blockchain technology will be superior to the privacy and security over user data which may be available through other means; that the Company's use of blockchain as part of its business model will improve access to genetic insights; and that the use of Ethereum in the Company's treasury management system will reflect a viable alternative to traditional fiat currencies, including the risk that commercial partners of the Company are or become unwilling to accept Ethereum as consideration for products and services.
Although management of the Company has attempted to identify important factors that could cause actual results to differ materially from those contained in forward-looking statements or forward-looking information, there may be other factors that cause results not to be as anticipated, estimated or intended. There can be no assurance that such statements will prove to be accurate, as actual results and future events could differ materially from those anticipated in such statements. Accordingly, readers should not place undue reliance on forward-looking statements and forward-looking information. Readers are cautioned that reliance on such information may not be appropriate for other purposes. The Company does not undertake to update any forward-looking statement, forward-looking information or financial out-look that are incorporated by reference herein, except in accordance with applicable securities laws.
Cryptocurrency Market Risks
The Company would like to remind investors that markets for cryptocurrencies have experienced much larger fluctuations than other markets, and there can be no assurances that significant swings in price will slow in the future. In the event that the price of cryptocurrencies decline, the value of an investment in the Company could also decline. As well, momentum pricing is typically associated with assets whose valuation, as determined by the investing public, accounts for anticipated future appreciation in value. Momentum pricing of cryptocurrency may result in speculation regarding future appreciation in the value of cryptocurrency. As a result, changing investor confidence could adversely affect an investment in the Company. Additionally, there is no assurance that cryptocurrency will become a leading means of digital payment. Any slowing or stopping of the development in the acceptance of cryptocurrency may adversely affect an investment in the Company. Furthermore, there is a risk that cryptocurrency trading platforms, or the Company's digital wallets may be compromised. Access to the Company's crypto-assets, maintained in a hosted online wallet, could also be restricted as a result of cyber crime. Any of these events may adversely affect the operations of the Company and, consequently, its business and profitability.
To view the source version of this press release, please visit https://www.newsfilecorp.com/release/248165
FAQ
What does Moss Genomics' OTC Markets listing (MSSGF) mean for U.S. investors?
What is Moss Genomics' Perennial platform currently in development?
On which exchanges does Moss Genomics (MSSGF) currently trade?
What is the main business focus of Moss Genomics (MSSGF)?
